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ScienceDirectAdequate response to severe influenza infections or pandemic
outbreaks requires two complementary strategies: preventive
vaccination and antiviral therapy. The existing influenza drugs,
M2 blockers and neuraminidase inhibitors, show modest
clinical efficacy and established or potential resistance. In the
past three years, several new agents have entered the clinical
pipeline and already yielded some promising data from Phase
2 trials. For two main categories, that is, the broadly neutralizing
anti-hemagglutinin antibodies and small-molecule inhibitors of
the viral polymerase complex, crystallography was
instrumental to guide drug development. These structural
insights also aid to expand the activity spectrum towards
influenza A plus B viruses, or conceive nucleoprotein or
polymerase assembly inhibitors. The practice of influenza
therapy should radically change in the next decade.
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Introduction
The annual influenza epidemics cause significant mor-
bidity and mortality, particularly in elderly or frail indi-
viduals. Worldwide, the number of severe influenza
infections is about 5 million each year leading to
500 000 deaths. About 75% of these fatalities are caused
by influenza A viruses; the other 25% is due to influenza B
virus. The widely recommended influenza vaccination
requires annual updating and is only partially effective in
some target populations. Besides, the influenza pandemic
of 2009 demonstrated our vulnerability to new and sud-
denly appearing influenza viruses for which pre-existing
immunity is lacking. Globally, the 2009 pandemic influ-
enza virus killed 300 000 people within only 18 months;
its death toll peaked in younger persons [1]. Influenza A
viruses circulating in swine or birds can enter the humanCurrent Opinion in Pharmacology 2016, 30:106–115 population and, hence, are a constant threat. For some
circulating avian influenza A viruses, the mortality in
humans is notoriously high, that is, 60% for H5N1
and 30% for H7N9.
As for antiviral therapy, virus resistance is widespread for
the M2 channel blockers amantadine and rimantadine,
and can also develop with the neuraminidase inhibitors
(NAIs) oseltamivir and, to a lesser degree, zanamivir [2].
These two NAIs were stockpiled by many countries in the
context of pandemic preparedness. Two newer analogues,
peramivir and laninamivir octanoate, were recently ap-
proved in some regions. In 2014, the NAIs became matter
of heavy debate after a Cochrane meta-analysis of clinical
reports [3] concluded that oseltamivir and zanamivir exert
only a small effect in shortening influenza disease in
adults. On the other hand, a similarly large meta-analysis
of individual patient data [4] determined that oseltamivir
does reduce the duration of influenza illness as well as the
risk for complications or hospitalization. Likewise, a study
involving >29 000 patients who were hospitalized during
the 2009 pandemic, demonstrated that the mortality risk
was significantly reduced upon early NAI treatment [5].
Hence, NAIs are advocated for patients who are at risk for
complicated influenza infections [6].
We here review the recent progress in antiviral drug
development for influenza. The (pre)clinical pipeline
contains diverse agents (Table 1) many of which target
the viral polymerase complex. Other approaches not
covered here are: inhibitors of the viral NS1 protein [7]
or host factors involved in virus replication [8], such as the
receptor destroying sialidase DAS-181 that is in Phase
2 clinical trials [9].
Next-generation neuraminidase inhibitors and
M2 channel blockers
Whereas the four NAIs mentioned above are reversible
transition state mimetics of the NA reaction, a new class
of 2,3-difluoro sialic acid derivatives was designed to bind
to NA in a covalent manner. These analogues displayed
favorable activity in influenza virus-infected cell culture
and mouse models [10]. The lead compound proved
active against the oseltamivir-resistant H275Y mutant
form of N1 neuraminidase, and was less affected than
zanamivir by the E119G neuraminidase mutation.
To address the issue of M2 blocker resistance, several
groups [11] are applying crystallographic and NMR struc-
tural insights as well as molecular dynamics simulations to
rationally develop new M2 inhibitors with activity against
wild-type M2, or the clinically relevant S31N or V27Awww.sciencedirect.com
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Table 1
Prototypic influenza inhibitors in various stages of (pre)clinical development
Name and structure Proposed action principlea Statusb References
Hemagglutinin inhibitors — broadly-neutralizing antibodies
CR6261 Binds to stem region
of A/group 1 HAs#§
Phase 2 [13,14]
CR8020 Binds to membrane-proximal
stem region of A/group
2 HAs#§
Phase 2 [13,14]
MHAA4549A Binds to HA stem epitope
conserved in influenza A
Phase 2a [18,19]
VIS410 Engineered antibody; binds to
HA stem epitope conserved in
influenza A
Phase 2a [64]
Hemagglutinin inhibitors — small molecules
Nitazoxanide
O O O S
N
NNH
+
O
O–CH3
Interferes with virus
maturation
Phase 3 [23,24]
Polymerase inhibitors
Favipiravir (T-705)
F N
N
O
OH
NH2
Nucleobase inhibitor#; causes
RNA chain termination and
virus mutagenesis
Approved (Japan)
Phase 3 (US/EU)
[31–37]
VX-787 (JNJ-872)
F
N N
N
N
F
NH
O
OH
H
Blocks the PB2-CBD
of influenza A#§
Phase 2b [38,40]
L-742,001
O
OHO
OH
Cl
N
Metal-chelating inhibitor of PA
endonuclease#§
Experimental [48–51]
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Table 1 (Continued )
Name and structure Proposed action principlea Statusb References
Compound ‘7’
N
N
N
O OH
HN
HN
F
Metal-chelating inhibitor of PA
endonuclease§
Experimental [52]
AL-794 (structure undisclosed) PA inhibitor Phase 1
S-033188 (structure undisclosed) PA inhibitor Phase 2
‘3670
O
O
CH3
N
N S
CI
Unknown (PB1?)# Experimental [53]
ASN2
N
N
HN
HN
S
O
NH
O
Unknown (PB1?)# Experimental [54]
‘Compound 10
O
O
O O
O
NH2
CH3
H3C Cl
N
Inhibits PAC-PB1N assembly Experimental [57,58
]
ANA-1
Cl
N N
N N
HO
H3C
CH3
Inhibits PAC-PB1N assembly Experimental [59]
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Table 1 (Continued )
Name and structure Proposed action principlea Statusb References
Nucleoprotein inhibitors
Nucleozin
O
N
O
N
N
CH3 CI
NO2
Causes NP aggregates;
specific for influenza A#§
Experimental [61]
Curcumin
HO
O
O O
O
OH
CH3
CH3
Interferes with RNA-binding
by NP
Experimental [62]
Naproxen
O
CH3
CH3
OH
O
Interferes with RNA-binding
by NP
Experimental [63]
a The # symbol denotes that the proposed action principle is supported by published resistance studies; the § symbol indicates that cocrystallization
data are available.
b In August 2016.mutant forms. One approach consists of adding an aro-
matic ring (‘warhead’) to the adamantane scaffold [12].
Targeting conserved sites in the viral
hemagglutinin
The 18 hemagglutinin (HA) subtypes of influenza A are
classified into two phylogenetic groups; the H1, H2 and
H5 HAs belong to group 1 whereas the H3 and H7 HAs are
in group 2. Also for influenza B, the circulating strains are
classified into two lineages (B/Victoria and B/Yamagata).
Despite high sequence diversity, some HA regions are
conserved within the same group or across both groups of
influenza A or B viruses. During recent years, several
broadly neutralizing antibodies (bnAbs) (reviewed in
[13,14]) with activity against group 1, group 2, or both
influenza A HA groups, were isolated from plasma samples
of influenza-infected or influenza-vaccinated individuals.
This created the prospect for monoclonal antibody-based
therapy. One bnAb (CR9114) recognizes an HA epitope
conserved in influenza A and B viruses [15]. The known
bnAb binding sites, revealed by cocrystallization, are
located at, firstly, an HA globular head region, in most
cases the receptor-binding site; secondly, an HA stem
domain with a key role in membrane fusion; or thirdly,
a membrane-proximal region at the base of the HA stemwww.sciencedirect.com [13,14]. Many bnAbs conferred protection in influenza-
infected mouse models, presumably by engaging immune
cells via Fc-FcgR interactions [16]. In vitro, the propensity
to select escape mutants is much higher for anti-globular
head than anti-stem bnAbs [13]. This does not exclude,
however, that some bnAb binding stem epitopes may be
prone to antigenic drift [17]. Several influenza bnAbs
(CR8020, CR6261, MEDI8852, CT-P27, MHAB5553A,
MHAA4549A and VIS410) are currently undergoing clini-
cal evaluation; for the latter two some limited clinical data
were recently disclosed [18,19].
A different agent interfering with the HA-mediated entry
process is Flufirvitide-3 (FF-3), a 16-mer HA peptide
sequence that entered Phase 1 trials [20]. The design of
small-molecule inhibitors towards conserved regions in
HA (such as the bnAb binding sites), seems particularly
difficult. Various fusion inhibitors were reported to pre-
vent HA refolding at low endosomal pH [21], but their
strict subtype-specificity and low resistance barrier have
been serious drawbacks for preclinical development. For
one H3-specific fusion inhibitor, the binding pocket in
the HA stem [22] lies adjacent to the binding site for
bnAb CR6261, emphasizing the key role of this region in
the processes of HA refolding and fusion.Current Opinion in Pharmacology 2016, 30:106–115
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Structure of the influenza A polymerase heterotrimer when bound to the vRNA promoter. In this open conformation, the enzyme is in its cap-
snatching mode with two functional domains, that is, PB2-CBD and PAN endonuclease, facing each other [pdb: 4WSB] [26
]. (a) Binding pose of
the PB2-CBD blocker VX-787 [pdb: 4P1U] [38]; the marked residues have a critical role in binding VX-787 or the cap analogue 7-methyl-GTP
[39]. (b) Binding mode of a PA inhibitor with hydroxypyridinone structure and potent enzyme inhibitory activity [pdb: 4M5U] [52]. The marked
residues have a crucial function in binding the divalent metal ions (purple spheres) or catalyzing RNA cleavage [44,45].An entirely unrelated mechanism applies to nitazoxanide,
a thiazolide compound that was proven effective against
influenza in a Phase 2b/3 clinical trial [23]. This small
molecule exhibits broad-spectrum activity against influ-
enza A and B besides many other viruses [24]. Its effect on
HA appears located at the posttranslational stage, since it
was shown to prevent HA transport to the host cell
membrane and exit of mature virus particles.
Inhibitors of the viral polymerase complex
Influenza A and B viruses have a single-stranded negative-
sense RNA genome divided into eight segments, in which
the viral RNA is covered with multiple nucleoprotein
molecules and attached to one copy of the viral polymer-
ase. This protein complex contains three subunits, PA,
PB1 and PB2, and basically has three functions: firstly,
binding of 50-capped host cell RNAs by the PB2 subunit;
secondly, cleavage of these RNAs by the PA endonuclease
to produce the primers for viral mRNA synthesis; and
thirdly, RNA elongation by the PB1 polymerase [25].
Recently, pioneering crystallographic analyses of theCurrent Opinion in Pharmacology 2016, 30:106–115 polymerase heterotrimer of influenza A, B or C
[26,27,28,29], have revealed intense inter-subunit
interactions and notable structural flexibility of this protein
complex, creating the opportunity to design allosteric
inhibitors. The PA-PB1-PB2 heterotrimer adopts an open
conformation when bound to the vRNA promoter
(Figure 1) [26,27], whereas a closed conformation is
seen in the apo-structure [28] and the protein complex
bound to a 50 cRNA fragment [29]. This pronounced
difference is related to ‘en bloc’ rotation of a large part of the
PB2 protein, and most probably signifies different func-
tional states of the polymerase complex, with the open
conformations representing the ‘cap-snatching’ and tran-
scription pre-initiation states [25].
Until 2014, structure-aided drug design of influenza poly-
merase inhibitors was based on crystal structures of partial
fragments that became available after 2008. Below, the
most successful strategies are briefly explained; a more
extensive description can be found elsewhere [30]. We
first describe the nucleobase analogue favipiravir, whichwww.sciencedirect.com
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most advanced polymerase inhibitor for influenza therapy.
Favipiravir (T-705)
This broad RNA virus inhibitor [31] was first reported in
2002. It was approved for influenza therapy in Japan in
2014, and is in Phase 3 trials in the USA and Europe. In
one Phase 2 study [19], favipiravir significantly reduced
the time to resolution of symptoms without evidence of
drug resistance in more than 700 samples tested. Mecha-
nistically, favipiravir acts as a competitive substrate in-
hibitor of the viral polymerase after its conversion to
favipiravir-ribosyl-50-triphosphate (T-705-RTP) [32].
The low efficiency of its activation [33] appears one
reason why favipiravir possesses relatively low antiviral
potency. In enzymatic influenza polymerase assays,
T-705-RTP mimics both GTP and ATP [34], indicating
that it acts as an ambiguous purine nucleotide due to its
rotating carboxamide. Although the unmodified ribose
allows RNA chain elongation, two consecutive T-705-
RTP incorporation events result in ‘leaky’ chain termi-
nation [35]. In cell culture, favipiravir appears to inhibit
viral RNA synthesis at high concentrations and produce
viral mutagenesis at lower concentrations [36]. Besides
having broad activity against influenza A and B, this drug
has the advantage of an exceptionally high barrier for drug
resistance. Until now, only one mutation (V43I in PB1;
obtained in virus-infected cell cultures under ribavirin
selection) was found to confer marginal (two-fold) resis-
tance to favipiravir [37]; the relevance of this substitution
still needs to be verified in enzymatic polymerase assays.
Inhibitors of cap-binding by PB2
The azaindole compound VX-787 (new code: JNJ-872) is
undergoing Phase 2b clinical evaluation after passing
successful evaluation in an influenza challenge study in
humans [19]. This promising agent displays nanomolar
activity in influenza A virus-infected cell cultures and acts
by interfering with cap-binding to PB2 [38].
The crystal structure of the cap-binding domain (CBD) of
PB2 in complex with 7-methyl-GTP was first revealed in
2008 [39]. Its recognition mechanism for capped RNA, in
which the methylated guanine interacts with two aromat-
ic residues in a cation-p sandwich, resembles that of other
cap-binding proteins such as the eukaryotic initiation
factor eIF4E. However, since the PB2-CBD has a distinct
protein fold with a unique cluster of Phe residues
(Figure 1, inset A), highly selective inhibitors are attain-
able. This is exemplified by VX-787, the product of
structure-aided drug design in which an azaindole scaf-
fold initially explored for inhibition of cellular kinases,
was rationally optimized towards the influenza PB2-CBD.
Its binding mode was clarified by cocrystallization
(Figure 1, inset A) and confirmed by resistance selection
in cell culture [40]. Development of PB2-CBD inhibitors
with equal activity against influenza A and B seemswww.sciencedirect.com challenging. Some residues (such as Phe-323) with a
crucial role in binding VX-787 in the influenza A PB2-
CBD, are not conserved in influenza B [41]. Also, the
PB2-CBD of influenza B is more flexible, explaining its
ability to recognize both methylated and unmethylated
cap structures, as demonstrated by cocrystallization
[41,42] and biochemical experiments [43].
Inhibitors of the PA endonuclease
In early 2016, two PA inhibitors entered Phase 1 (AL-794)
or Phase 2 (S-033188) clinical trials. The N-terminal part
of PA (PAN) carries the catalytic domain for cleavage of
the capped host RNAs. Its core region contains one or two
divalent metal ions (Mn2+ or Mg2+) and several residues
that are conserved among influenza A and B viruses, given
their role in catalysis or metal ion coordination (Figure 1,
inset B) [44,45]. This catalytic center is surrounded by
distinct hydrophobic pockets that are well suited for drug
design [46,47]. Hence, PA inhibitor design is currently
built on chemical scaffolds bearing coplanar oxygens with
the right geometry to coordinate the divalent metal ion(s),
and to which hydrophobic elements have been added.
The b-diketo acid derivative L-742,001 [48] serves as a
prototype since it is the only reported inhibitor for which
target and PAN binding mode have been confirmed in cell
culture-based virus resistance studies [49–51]. Screening
efforts with isolated PAN enzyme have yielded diverse
PA inhibitors (see [46,47] for examples). Quite a few of
these hit compounds display only weak activity in virus-
infected cell cultures, which is likely related to low cell
penetration and/or insufficient antiviral selectivity. Crys-
tallographic fragment screening plus hit optimization [52]
delivered a hydroxypyridinone-based lead compound
with remarkable potency (i.e. IC50 value of 11 nM in a
PAN enzyme assay), suggesting that its metal chelating
motif and binding pose within PAN (Figure 1, inset B) are
particularly relevant.
Inhibitors of the PB1 polymerase
The recent revelation of the active site structure of
PB1 within the PA-PB1-PB2 heterotrimer [26,27]
enables to rationally design inhibitors against this
RNA-dependent RNA polymerase. Two possible lead
compounds, identified by serendipitous screening, are
compounds ‘3670 [53] and ‘ASN20 [54] which both select
for a resistance mutation located at the outside of PB1, i.e.
H456P for ‘3670 and S499T for ‘ASN20. The conception of
PB1 inhibitors towards the catalytic center for RNA
elongation would be facilitated by a crystal structure of
PB1 (or the polymerase heterotrimer) in complex with a
natural NTP or structural analogue such as T-705-RTP.
Protein–protein interaction (PPI) inhibitors
In the crystal structure of PAC (the C-terminal domain of
PA) in complex with the PB1 N-terminus (PB1N; residues
1–25), the binding pocket in PAC resembles a ‘dragon’s
head’ that clamps the PB1N peptide into its ‘jaws’ [55,56].Current Opinion in Pharmacology 2016, 30:106–115
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Figure 2
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Binding mode of nucleozin, a compound that forms bridges between NP monomers resulting in NP aggregation [65]. The inset shows the
structure of nucleozin (in pink) and residues aligning its binding pocket [pdb: 3RO5] [61].The small size and hydrophobic nature of this pocket
provided the foundation to design small-molecule PAC-
PB1N assembly inhibitors, the first of which were
reported in 2012 [57]. These prevent the PAC-PB1N
interaction in biochemical assays and inhibit cell culture
growth of influenza A (and, in some cases, also influenza
B) virus (see [58] and references therein). Compound
‘ANA-1’ was shown to be effective in an influenza mouse
model [59]. Cocrystallization or resistance studies with
these PPI inhibitors are required to understand their
precise binding mode within PAC.
Nucleoprotein-binding agents
The viral nucleoprotein (NP) is an attractive drug target
since it is well conserved and has multiple regulatory and
structural functions. To cover the viral RNA, it forms NP
oligomers in which the tail loop inserts into the body
domain of another NP molecule, and the RNA is bound in
a groove lined by basic residues. Diverse small-molecule
NP inhibitors with activity in virus-infected cell cultures
have been discovered (see [60] and references therein).
For the NP-aggregating agent nucleozin, the binding site
in NP was identified by cocrystallization (Figure 2) and
viral resistance studies [61]. Nucleozin displayed nice
efficacy in influenza mouse models, yet is inactive
against some influenza strains with pre-existing resis-
tance. This issue could be solved by targeting the highlyCurrent Opinion in Pharmacology 2016, 30:106–115 conserved RNA binding groove, such as seen with the
known pharmacological agents curcumin [62] and
naproxen [63].
Conclusion
During the past five years, enormous progress has been
made in revealing the structure of several conserved
influenza protein domains, creating ample opportunities
for inhibitor design. We here briefly reviewed some
concepts targeting the viral hemagglutinin, polymerase
complex or nucleoprotein, for which antiviral leads are in
the (pre)clinical stage. It can be anticipated that new
influenza blockers will achieve market approval within
the forthcoming years. Given the high sequence variation
and mutability of influenza A and B viruses, we need an
arsenal of drugs with different action mechanisms and
resistance profiles, to address severe influenza infections
in a population that is ageing and highly susceptible to
new influenza viruses with pandemic potential.
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